Press

Bright Minds Announces Overnight Marketed Offering of Units

Aug 23 • 4 min read

Bright Minds Biosciences Inc. (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, is pleased to announce that is has entered into a letter of engagement with Eight Capital, under which Eight Capital has been appointed as agent in connection with the offer…

Universal Ibogaine Provides Update on Kelburn Recovery Center

Aug 22 • 3 min read

Universal Ibogaine Inc. (TSXV: IBO | OTC: IBOGF) is a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care. Ibogaine is a plant derived medicine used in addiction treatment and has been shown to deliver detoxification from opioids, heroin and other substances, and can provide a several month window free of drug cravings….

Lobe Sciences Announces Update on Corporate Slide Deck Highlighting its Psilocin Compounds and Development Plans

Aug 22 • 2 min read

Lobe Sciences Ltd. (CSE: LOBE | OTCQB: LOBEF), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has updated its Corporate Slide Deck which among other initiatives, describes its plans for advancing the development of its psilocin analogues L-130 and L-131. Philip Young, CEO…

Core One Labs’ Akome Achieves Another Milestone in Development of its Psychedelic Drug Formulas and Announces Positive Results from Neuro-Pharmacokinetics Studies

Aug 22 • 3 min read

Core One Labs Inc. (CSE: COOL | OTCQB: CLABF | Frankfurt: LD6 | WKN: A3CSSU) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. through its formalized research agreement with Fundación Medina in Granada, Spain has received very encouraging results from pharmacokinetics studies currently underway. The study results represent another significant milestone in…

PharmAla Biotech to supply Major Australian Research Institute with LaNeo™ MDMA for Phase 3 Clinical Trial

Aug 22 • 2 min read

PharmAla Biotech is proud to have been selected as the MDMA manufacturing partner for the a major Australian Research institute’s Phase 3 clinical trial. With the product release of PharmAla’s LaNeo™ MDMA earlier this month now complete, researchers across the globe now have a new option to drive their research. “Having completed our value chain for…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435